Clinical Trial Update: Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial assessing lorlatinib together with local consolidation therapy for patients with ALK-positive advanced non-small cell lung cancer; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Lorbrena (lorlatinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Advanced Non-Small Cell Lung Cancer | Phase 2 | Status: NOT_YET_RECRUITING